TY  - BOOK
AU  - Koffas A
AU  - Mak L Y
AU  - Gill U S
AU  - et al
TI  - Early treatment consideration in patients with hepatitis B ‘e’ antigen-positive chronic infection: is it time for a paradigm shift? 
T2  - Viruses
PY  - 2022///
CY  - Basel SWI
PB  - MDPI
KW  - Treatment & research: Medical treatment
N2  - To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk of HCC. Historically, patients with hepatitis B ‘e’ antigen (HBeAg)-positive chronic infection, were not offered antiviral therapy. The current review discusses the reasons to consider early antiviral therapy in HBeAg-positive chronic infection.

Related terms Hep B, HBV
UR  - https://www.mdpi.com/1999-4915/14/5/900
ER  -